A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.
OBJECTIVE
To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue.


METHODS
Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Generalized estimating equation (GEE) models were used to estimate the treatment effect on changes in limb fat mass.


RESULTS
In the combined dataset of 427 patients, the baseline median age was 45 years, 86% were male, 80% were Caucasian, 63% were receiving stavudine (d4T) or zidovudine (AZT), 66% were on protease inhibitors, and median body mass index was 23 kg/m(2). In a univariate GEE model, TZD was associated with an increase in limb fat mass (coeff = 0.14 kg vs placebo, P = .04). In a multivariable GEE model, patients receiving pioglitazone had significantly higher limb fat mass gains (coeff = 0.35 kg, P < or = .01) compared to patients receiving placebo, while patients on rosiglitazone did not (coeff = 0.05 kg, P = .48). Interactions between thymidine analogue use and rosiglitazone and pioglitazone were not significant.


CONCLUSIONS
In this meta-analysis, pioglitazone therapy was more effective than placebo to increase limb fat mass whereas rosiglitazone was not significantly better than placebo. The effectiveness of these drugs did not vary according to whether the patients were receiving thymidine analogues.
Raboud
Janet M
JM
University of Toronto, Toronto, Canada. raboud@lunenfeld.ca
Diong
Christina
C
Carr
Andrew
A
Grinspoon
Steven
S
Mulligan
Kathleen
K
Sutinen
Jussi
J
Rozenbaum
William
W
Cavalcanti
Rodrigo B
RB
Wand
Handan
H
Costagliola
Dominique
D
Walmsley
Sharon
S
D000328:Adult; D050218:Body Fat Distribution; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D008060:Lipodystrophy / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000009:adverse effects
D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
J Infect Dis. 2005 May 15;191(10):1686-96
15838796
AIDS. 2004 Apr 30;18(7):1029-36
15096806
J Infect Dis. 2008 Dec 15;198(12):1794-803
18954260
Antivir Ther. 2008;13(1):67-76
18389900
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):367-71
15776544
J Infect Dis. 2007 Jun 15;195(12):1754-61
17492590
JAMA. 2007 Sep 12;298(10):1189-95
17848653
N Engl J Med. 2007 Jun 14;356(24):2457-71
17517853
AIDS. 2003 May 2;17(7):971-9
12700446
Ann Intern Med. 2000 Aug 15;133(4):263-74
10929166
AIDS. 2006 Oct 24;20(16):2043-50
17053350
AIDS. 2002 Feb 15;16(3):353-8
11834946
AIDS. 2002 Jan 4;16(1):13-20
11741158
Metabolism. 1999 Sep;48(9):1102-7
10484048
Biometrics. 1986 Mar;42(1):121-30
3719049
JAMA. 2002 Jul 10;288(2):207-15
12095385
Clin Infect Dis. 2004 Jan 15;38(2):263-70
14699460
AIDS. 2009 Jun 1;23(9):1109-18
19417580
AIDS. 1999 Sep 10;13(13):1659-67
10509567
Ann Intern Med. 2004 May 18;140(10):786-94
15148065
Antimicrob Agents Chemother. 2002 Mar;46(3):716-23
11850253
Diabetes Care. 1999 Jun;22(6):908-12
10372240
AIDS. 2005 Nov 4;19(16):1807-18
16227788
Arch Intern Med. 2004 Oct 25;164(19):2097-104
15505122
Lancet. 2001 Mar 3;357(9257):651-2
11247544
Am J Ther. 2008 Nov-Dec;15(6):506-11
19127132
Lancet. 2001 Mar 3;357(9257):686-7
11247555
AIDS. 2007 Jan 2;21(1):47-57
17148967
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40
17057609
Lancet. 1999 Sep 25;354(9184):1112-5
10509516
N Engl J Med. 2005 Jan 6;352(1):48-62
15635112
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47
17106274
Lancet. 2004 Feb 7;363(9407):429-38
14962523
AIDS. 2010 Jun 1;24(9):1291-8
20453626
J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):163-70
12394794
Antivir Ther. 2003 Jun;8(3):199-207
12924536
J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33
12792352